Liver disease is often described as a silent threat, but researchers at the University of Toledo say one of its earliest biological signals may be hiding in plain sight inside ordinary blood samples. Their study suggests that elevated bile acids, compounds normally kept within a tightly controlled circulation between the liver and intestine, produce a measurable change in the physical behavior of red blood cells. That change could form the basis of a rapid screening test capable of flagging hepatobiliary problems before symptoms or conventional liver markers become apparent.
The discovery centers on cholemia, a condition in which bile acids accumulate in the bloodstream. Bile acids are synthesized in the liver from cholesterol and released into the intestine, where they help break down and absorb dietary fats. Most are then recovered and returned to the liver through the portal circulation. When liver cells are damaged or the flow of bile is obstructed, this recycling system becomes disrupted. Bile acids can then spill into the general circulation, where their concentration rises. Although high levels may eventually cause itching, jaundice, abdominal discomfort or other symptoms, early elevations can remain clinically invisible.
“Bile acids are a very neglected analyte in the clinics,” said Dr. Matam Vijay-Kumar, a professor of physiology and pharmacology at the University of Toledo’s College of Medicine and Life Sciences. Routine blood panels commonly measure cholesterol, glucose, triglycerides and enzymes associated with liver injury, but bile acids are not typically included. According to Vijay-Kumar, that omission may allow disease to advance during a period when lifestyle changes, closer observation or targeted treatment could still make a meaningful difference. The team’s proposed approach is not intended to replace established diagnostic testing, but to provide an early warning that prompts more comprehensive evaluation.
The researchers initially expected elevated bile acids to weaken red blood cells. Because bile acids interact with biological membranes, the logical prediction was that prolonged exposure would make erythrocytes more fragile and more likely to rupture. Instead, experiments produced the opposite result. Red blood cells collected from mice with elevated circulating bile acids resisted osmotic rupture more effectively than cells from healthy animals. The pattern was observed across several genetically distinct mouse models, suggesting that it was not an isolated consequence of one particular form of experimental liver disease.
The investigators then examined whether the same phenomenon occurred in people. Blood samples from 23 patients with cholestatic liver disease treated at the University of Toledo Medical Center were compared with samples from 23 healthy controls. The red blood cells from patients with elevated bile acids displayed greater resistance to osmotic stress than those from the control group. In an osmotic fragility test, blood cells are placed in solutions with different salt concentrations. Water moves into the cells in dilute solutions, causing them to swell and eventually rupture. Cells with altered membranes withstand this pressure longer, producing a characteristic response that can be measured.
Further analysis indicated that the change was rooted in the composition of the erythrocyte membrane. Red blood cells exposed to high bile acid concentrations accumulated more cholesterol while losing phospholipids, the major structural lipids that form the membrane’s flexible bilayer. The resulting shift in the cholesterol-to-phospholipid balance appeared to stiffen the membrane. A more rigid membrane can make erythrocytes less vulnerable to the swelling forces generated during osmotic challenge. In this case, the cells’ unusual toughness becomes a measurable proxy for a chemical disturbance occurring elsewhere in the body.
That physical response could allow clinics to detect elevated bile acids using a small amount of whole blood and equipment already familiar in routine testing environments. Vijay-Kumar said the proposed assay could use approximately four microliters of additional blood, place it into a prepared solution and produce a result after roughly 10 to 20 minutes. “We can identify people with high bile acids with 100 percent accuracy,” he said, referring to the separation observed in the study’s experimental sample. That figure should be interpreted cautiously, however, because the human comparison involved only 46 participants and will need to be tested in larger, more diverse clinical populations before the method can be considered validated for general screening.
The potential application is especially significant in pregnancy, when cholestasis can expose both mother and fetus to serious complications. Intrahepatic cholestasis of pregnancy is associated with elevated maternal bile acids and can increase the risk of premature delivery, fetal distress and stillbirth. Vijay-Kumar said concentrations above 40 micromolar are a level at which fetal injury becomes a major concern and careful monitoring may be required. A fast test that identifies rising bile acids could help clinicians intensify surveillance and make timely decisions about treatment or delivery. It could also be useful in patients with suspected bile duct obstruction, drug-induced liver injury or other forms of hepatobiliary dysfunction.
The study does not show that the red-cell assay can diagnose a specific liver disease, nor does it establish that every person with elevated bile acids will display the same membrane response. The research combined animal experiments with a small human observational comparison, and the published study metadata identifies the primary work as an experimental study involving animals. Before the test could enter routine care, independent researchers would need to confirm its performance across different ages, ethnic backgrounds, pregnancy stages and disease severities. They would also need to determine how medications, anemia, metabolic disorders and other changes in red-cell biology might influence the result.
The University of Toledo research team has filed a patent application titled “Rapid Screening for Elevated Bile Acids Using Whole Blood,” identified as application number 18844313. The work, published in the American Journal of Physiology—Gastrointestinal and Liver Physiology, presents the red-cell response as a potential first-line signal rather than a final diagnosis. If larger studies confirm the findings, a simple osmotic-resistance test could add a new layer to standard blood screening, identifying biochemical stress before conventional markers rise sharply or symptoms appear. In that sense, the most important discovery may not be that diseased blood cells become stronger, but that their unexpected resilience could reveal when the liver is beginning to fail.
Subject of Research: Animals, with blood samples from human patients and healthy controls also analyzed
Article Title: Elevated circulating bile acids driven erythrocyte osmotic resistance marks hepatobiliary disease
News Publication Date: 3-Aug-2026
Web References: University of Toledo; American Journal of Physiology—Gastrointestinal and Liver Physiology: https://journals.physiology.org/journal/ajpgi
References: DOI: 10.1152/ajpgi.00096.2026
Keywords: liver disease, bile acids, cholemia, red blood cells, erythrocytes, osmotic resistance, cholestatic liver disease, hepatobiliary disease, pregnancy, diagnostic screening
Tags: bile acids as liver health biomarkersblood sample analysis for liver healthblood test for hepatobiliary problemscholemia blood markerinnovative liver disease diagnostic toolsliver damage early signsLiver disease early detectionoverlooked liver disease indicatorsrapid liver disease screening methodsred blood cell physical behavior changessilent liver disease screeningUniversity of Toledo liver research
